Evidence map›Paper›PMID 24116940›Full record

ArticleAssay and drug development technologies2013

Expression and purification of recombinant human apolipoprotein A-II in Pichia pastoris.

Manman Su, Yitian Qi, Mingxing Wang, Weiqin Chang, Shuang Peng, Tianmin Xu, Dingding Wang

Open access · greenAbstract read
In one paragraph

Article in Assay and drug development technologies, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 63% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 1 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 4 institutions in 1 country.

Manman Su1 Department of Regenerative Medicine, College of Pharmacy, Jilin University , Changchun, China .
Yitian Qi
Mingxing Wang
Weiqin Chang
Shuang Peng
Tianmin Xu
Dingding Wang
Jilin University · CNSecond Affiliated Hospital of Jilin University · CNChangchun University of Chinese Medicine · CNGuangdong Pharmaceutical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Apolipoprotein A-II (ApoA-II) is the second most abundant protein constituent of high-density lipoprotein (HDL). The physiologic role of ApoA-II is poorly defined. ApoA-II may inhibit lecithin:cholesterol acyltransferase and cholesteryl-ester-transfer protein activities, but may increase the hepatic lipase activity. ApoA-II may also inhibit the hepatic cholesteryl uptake from HDL probably through the scavenger receptor class B type I depending pathway. Interpretation of data from transgenic and knockout mice of genes involved in lipoprotein metabolism has been often complicated as clinical implications because of species difference. So it is important to obtain human ApoA-II for further studies about its functions. In our studies, Pichia pastoris expression system was first used to express a high-level secreted recombinant human ApoA-II (rhApoA-II). We have cloned the cDNA encoding human ApoA-II and achieved its high-level secreting expression with a yield of 65 mg/L of yeast culture and the purification process was effective and easy to handle. The purified rhApoA-II can be used to further study its biological activities.

Indexed as

Alcohol OxidoreductasesApolipoprotein A-IIBlotting, WesternCloning, MolecularCulture MediaDNA, ComplementaryElectrophoresis, Polyacrylamide GelEnzyme-Linked Immunosorbent AssayFermentationGenetic VectorsHumansIndicators and ReagentsLiposomesMethanolPichiaPromoter Regions, GeneticAlcohol OxidoreductasesApolipoprotein A-IICulture MediaDNA, ComplementaryIndicators and ReagentsLiposomesMethanolRecombinant Proteins

Identifiers

PMID24116940
PMCPMC3804080
OpenAlexW3023754960

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.